Recent 8-K filings for MREO

• August 19, 2026, 7:52 AM ET regulatory materiality 0.60 negative item 3.01

  Mereo BioPharma gets second Nasdaq notice; extra 180 days to meet $1 bid price

  Received second Nasdaq notice on Aug 18, 2026; new compliance deadline Feb 16, 2027.

• August 11, 2026, 8:26 AM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Mereo Q2 net loss narrows to $7M; Sentynl alvelestat option deal worth up to $475M

  Q2 2026 net loss $7.0M vs $14.6M in Q2 2025; R&D down $3.6M to $1.8M.

• August 11, 2026, 8:07 AM ET M&A materiality 0.80 positive item 1.01item 7.01item 9.01

  Mereo, Sentynl sign option/license deal for alvelestat in AATD-LD; up to $40M upfront, $435M milestones

  Non-refundable option fee; on exercise $40M upfront/R&D, up to $435M milestones, double-digit tiered royalties on US sales.

• May 12, 2026, 8:56 AM ET earnings materiality 0.95 negative item 2.02item 2.01item 9.01 ◈ Earnings Releases

  Mereo BioPharma Q1 net loss $6.7M; setrusumab Phase 3 fails primary endpoint, regulator engagement begun

  Net loss of $6.7M in Q1 2026 vs $12.9M in Q1 2025; cash and equivalents $36.2M as of March 31, 2026.

• March 19, 2026, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01 ◈ Earnings Releases

  Mereo BioPharma FY2025 net loss $41.9M; setrusumab Phase 3 studies miss primary endpoints, show BMD gains

  Cash $41.0M as of Dec 31, 2025; expected runway into mid-2027 (from $69.8M end 2024).

• January 12, 2026, 6:59 PM ET other material materiality 0.85 negative item 7.01item 8.01item 9.01

  Mereo BioPharma reports setrusumab Phase 3 miss; extends cash runway to mid-2027

  Cash and equivalents $41M as of Dec 31, 2025; reduced pre-commercial spend extends runway to mid-2027.

• December 29, 2025, 6:59 PM ET other material materiality 0.85 negative item 7.01item 8.01item 9.01

  Mereo setrusumab Phase 3 trials miss primary fracture endpoints; BMD improvements seen

  Neither ORBIT (placebo) nor COSMIC (bisphosphonate) achieved statistical significance on annualized clinical fracture rate.

• November 10, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Mereo BioPharma Q3 2025 net loss narrows to $7.0M; cash $48.7M; setrusumab data expected year-end

  Net loss of $7.0M in Q3 2025 vs $15.0M in Q3 2024; operating loss of $10.0M.

• July 10, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01

  Mereo BioPharma and Ultragenyx Provide Update on Phase 3 Orbit and Cosmic Studies of UX143 in Osteogenesis Imperfecta

  The Phase 3 Orbit study final analysis is expected around end of 2025, with a threshold of p<0.04.

• May 13, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Mereo BioPharma Q1 net loss $12.9M; setrusumab Phase 3 Orbit on track for mid-year readout

  Net loss widened to $12.9M (Q1 2024: $9.0M) on operating loss of $11.2M.

• March 26, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Mereo BioPharma FY2024 net loss $43.3M; cash $69.8M funds operations into 2027

  Net loss of $43.3M in FY2024 vs $29.5M in FY2023; R&D expenses rose $3.5M to $20.9M driven by alvelestat and setrusumab.

• January 13, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Mereo BioPharma: setrusumab Phase 3 Orbit 2nd interim analysis mid-2025; alvelestat gets positive EMA orphan opinion

  Phase 3 Orbit study of setrusumab in OI progressing to second interim analysis expected mid-2025; final analysis possible Q4 2025.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 1.01item 2.02item 9.01

  Mereo BioPharma Q3 net loss $15M; cash $80.5M; amends AstraZeneca deal with $114.3M milestone potential

  Amended AstraZeneca license agreement modifies development milestones; potential future payments up to $114.3M in cash and ADSs; issued 2.04M shares and paid $0.5M.

• August 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Mereo BioPharma Q2 net loss $12.3M; setrusumab studies fully enrolled, fracture rate cut 67%

  Cash $87.4M as of June 30, 2024, including $50M June offering; runway into 2027.

• June 14, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 7.01item 9.01

  Mereo BioPharma prices $50M registered direct offering of 12.5M ADS at $3.99/ADS

  Gross proceeds $50M from 12,531,300 ADS at $3.99 each; net proceeds ~$45.9M after expenses.

• June 12, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Setrusumab Phase 2 data: 67% fracture rate reduction in OI at 14 months

  Median annualized fracture rate reduced 67% to 0.00 (p=0.0014, n=24) vs pre-treatment 0.72.

• May 15, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Mereo BioPharma Q1 net loss $9.0M, cash $48.7M; setrusumab enrollment complete

  Net loss $9.0M in Q1 2024 vs $12.1M in Q1 2023; operating loss $9.9M.

• March 27, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Mereo BioPharma reports FY2023 revenue $10M, net loss $29.5M; cash $57.4M funds ops into 2026

  Revenue $10.0M from Ultragenyx milestone and ReproNovo upfront; net loss $29.5M vs $42.2M in 2022.

• January 8, 2024, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Setrusumab OI trials on track; alvelestat FDA alignment; leflutrozole licensed for up to $64.25M

  Setrusumab: Phase 3 Orbit study (195 patients) expected full enrollment around end Q1 2024; Cosmic study (~65 patients) expected full enrollment 1H 2024.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.65 · Most common event earnings

6 positive 6 negative 15 neutral

source · MREO on sec.gov